FILGRASTIM
Malignant Neoplasms of Brain
St. Jude Children's Research Hospitalprotein_peptidePhase 2Dormant
B
63/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 48/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Malignant Neoplasms of Brain cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FLUTICASONE John Sampson | Phase 2 | B |
Sargramostim John Sampson | Phase 2 | B |
Pep-3 Vaccine John Sampson | Phase 2 | B |
Pep-3-Klh John Sampson | Phase 1 | CC |
Tetanus Toxoid Gary Archer Ph.D. | Phase 1 | CC |
View all 9 →
Same molecule, other indications
FILGRASTIM is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →